Adaptive Biotechnologies director Robert Hershberg sells $748k in shares

Robert Hershberg, a director at Adaptive Biotechnologies Corp, divested 30,664 shares on August 18, 2026, as documented in a recent regulatory filing. The sale comprised two transactions: 15,000 shares sold at an average price of $24.39, and 15,664 shares sold at an average price of $24.41. Hershberg’s previous investment of 15,000 shares, acquired through exercised stock options at $6.32 per share, totaled $94,800.

Post-transactions, he currently holds 46,683 shares of Adaptive Biotechnologies common stock. Concurrently, ADPT's stock price hovered near its 52-week peak of $26.16, having surged by 107% over the past year. Analysts perceive the stock as potentially overvalued relative to its Fair Value, with InvestingPro suggesting 13 ProTips and a detailed Pro Research Report.

Despite a mixed second-quarter report, where the company incurred an adjusted loss of $0.25 per share against an estimated $0.14 loss, revenue exceeded expectations at $71.6 million, marking a 22% increase from the previous year. Revenue growth reflects a robust 49% rise in the minimal residual disease business and a 43% increase in clonoSEQ MRD test franchise volume usage.

BTIG and Guggenheim both raised their price targets for ADPT to $25, maintaining Buy ratings, citing strong volume performance and high usage among clonoSEQ clients as justification.